Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Porter

Showing results (71-80 of 125) with videos related to

Pageof 13
Sort By:
European Journal of Haematology|February 19, 2015
Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatmentJohn B Porter, Mohsen El-Alfy, Vip Viprakasit, et al.
Haematologica|April 16, 2013
Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC studyJong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, et al.
American Journal of Hematology|July 27, 2023
SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteersJohn B Porter, Alison Scrimgeour, Alberto Martinez, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 24, 2007
Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial ironMark A Westwood, Lisa J Anderson, Alicia M Maceira, et al.
American Journal of Hematology|January 22, 2019
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysisAli T Taher, Raffaella Origa, Silverio Perrotta, et al.
European Heart Journal|April 24, 2010
Relation of myocardial T2* to right ventricular function in thalassaemia majorFrancisco Alpendurada, John-Paul Carpenter, Monica Deac, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|May 8, 2016
Detection of metallic cobalt and chromium liver deposition following failed hip replacement using T2* and R2 magnetic resonanceAmna Abdel-Gadir, Reshid Berber, John B Porter, et al.
European Journal of Haematology|November 25, 2014
Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA studyYesim Aydinok, John B Porter, Antonio Piga, et al.
Pediatric Blood & Cancer|September 1, 2016
One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantationAdlette Inati, Mario Kahale, Nada Sbeiti, et al.
Haematologica|December 22, 2010
A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overloadHugh Young Rienhoff, Vip Viprakasit, Lay Tay, et al.
Pageof 13

Showing results (71-80 of 125) with videos related to

Sort By:
Pageof 13
European Journal of Haematology|February 19, 2015
Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatmentJohn B Porter, Mohsen El-Alfy, Vip Viprakasit, et al.
Haematologica|April 16, 2013
Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC studyJong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, et al.
American Journal of Hematology|July 27, 2023
SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteersJohn B Porter, Alison Scrimgeour, Alberto Martinez, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 24, 2007
Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial ironMark A Westwood, Lisa J Anderson, Alicia M Maceira, et al.
American Journal of Hematology|January 22, 2019
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysisAli T Taher, Raffaella Origa, Silverio Perrotta, et al.
European Heart Journal|April 24, 2010
Relation of myocardial T2* to right ventricular function in thalassaemia majorFrancisco Alpendurada, John-Paul Carpenter, Monica Deac, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|May 8, 2016
Detection of metallic cobalt and chromium liver deposition following failed hip replacement using T2* and R2 magnetic resonanceAmna Abdel-Gadir, Reshid Berber, John B Porter, et al.
European Journal of Haematology|November 25, 2014
Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA studyYesim Aydinok, John B Porter, Antonio Piga, et al.
Pediatric Blood & Cancer|September 1, 2016
One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantationAdlette Inati, Mario Kahale, Nada Sbeiti, et al.
Haematologica|December 22, 2010
A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overloadHugh Young Rienhoff, Vip Viprakasit, Lay Tay, et al.
Pageof 13